Aim To evaluate the demographic and clinical data of fifty two patients with the diagnosis of ulcerative colitis. Methods A total of 52 patients diagnosed with ulcerative colitis by clinical, endoscopical and histopathological evaluations were included the study. Demographic data, colon involvement site of the disease and disease severity were examined from the patients' records. The patients were divided into groups according to the Baron grading system. Results Distribution of patients according to the colon involvement site was: 10 (9.2%) rectal, 16 (30.8%) rectosigmoid, 13 (25%) left sided, 10 (19.2%) extensive colitis and 3 (5.8%) pancolitis. According to colon involvement sites and Baron classification the results were: five (9.6 %), two (3.8%) and three (5.7%) patients with ulcerative proctitis were at grade 1, 2 and 3, respectively. Two (3.8%), six (11.5 %), six (11.5 %) and two (3.8%) patients with rectosigmoid ulcerative colitis were at grade 0, 1, 2 and 3, respectively. Four (7.6 %), five (9.6%) and four (7.6%) patients with left sided ulcerative colitis were at grade 1, 2, and 3, respectively. One (1.9 %), three (5.7%), and six (11.5 %) patients with extensive ulcerative colitis were at grade 1, 2 and 3, respectively. All three (5.7%) patients with pancolitis were at grade 3 (p=0.11) Conclusion The ratio of pancolitis is found to be lower in our series. There was no statistically significant difference among the genders according to the age, involvement site and the severity of the disease as well as according to the colon involvement sites and grading.
Ma A-S, Kalaoui M, Patty I, Hasan F, Khajah A, Al-Nakib B. Ulcerative colitis in Kuwait: a review of 90 cases. Digestion 2003:218–24.
2
Su C, Lichtenstein G. Diagnosis of Crohn’s disease: A wolf in sheep’s clothing? Am J Gastroenterol 2000:3345–50.
3
Kühbacher T, Scheiber S, Fölsch U. Ulcerative colitis: conservative management and long term effects. Langenbecks Arch Surg 2004:350–3.
4
Ozdil S, Akyüz F, Pinarbasi B, Demir K, Karaca C, Boztas G, et al. Ulcerative colitis: analyses of 116 cases (do extraintestinal manifestations effect the time to catch remission? Hepatogastroenterology 2004:768–70.
5
Björck S, Dahiström A, Ahlman H. Treatment of distal colitis with local anaesthetic agents. Pharmacol Toxicol 2002:173–80.
6
Balai H, Asadzadeh A, Aghdaei H, Farnood A, Habibi M, Mafi A, et al. Time trend analysis and demographic features of inflammatory bowel disease in Tehran. Gastroenterol Hepatol Bed Bench 2015:253–61.
7
Shirazi K, Somi M, Bafandeh Y, Saremi F, Mylanchy N, Rezaeifar P, et al. Epidemiological and clinical characteristics of inflammatory bowel disease in patients from northwestern iran. Middle East J Dig Dis 2013:86–92.
8
Regueiro M. Diagnosis and treatment of ulcerative proctitis. J Clinic Gastroenterol 2004:733–40.
9
Karaman A, Hamurcu Z, Donmez H, Bitken N, Karaman H, Baskol M, et al. Investigation of genome instability in exfoliated colonic epithelial cells and mitogenstimulated lymphocytes of patients with ulcerative colitis. Digestion 2012:228–35.
10
Tahara T, Inoue N, Hisamatsu T, Kashiwagi K, Kanai T, Watanabe M, et al. Clinical significance of microsatellite instability in the inflamed mucosa for the prediction of colonic neoplasms in patients with ulcerative colitis. J Gastroenterol Hepatol 2005:710–5.
11
Ekbom A, Helmick C, Zack M, Ho A. Ulcerative colitis and colorectal cancer: a population -based study. N Engl J Med 1990:357–9.
12
Karlén P, Löfberg R, Broström O, Leijonmarck C, Hellers G, Persson P. Increased risk of cancer in ulcerative colitis: A population-based cohort study. Am J Gastroenterol 1999:1047–52.
13
Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med 2011:1713–25.
14
Ozin Y, Kılıç M, Nadir I, Cakal B, Disibeyaz S, Arhan M, et al. Clinical features of ulcerative colitis and Crohn’ s disease in Turkey. J Gastrointestin Liver Dis 2009:157–62.
15
Gong W, Lv N, Wangetal B. Risk of ulcerative colitis-associated colorectal cancer in China: a multi-center retrospective study. Dig Dis Sci 2012:503–7.
16
Jiang X, Cui H. An analysis of 10218 ulcerative colitis cases in China. World J Gastroenterol 2002:158–61.
17
Wong S, Ng S. What can we learn from inflammatory bowel disease in developing countries? Current Gastroenterol Rep 2015:313.
18
Li J, Wang F, Zhang H, Sheng J, Yan W, Ma M, et al. Coticosteroid therapy in ulcerative colitis: clinical response and predictors. World J Gastroenterol 2015:3005–15.
19
Orholm M, Munkholm P, Langholz E, Nielsen O, Sørensen T, Binder V. Familial occurrence of inflammatory bowel disease. N Engl J Med 1991:84–8.
20
Andreu M, Márquez L, Domènech E, Gisbert J, García V, Marín-Jiménez I, et al. Disease severity in familial cases of IBD. J Crohns Colitis 2014:234–9.
21
Moller F, Andersen V, Wohlfahrt J, Jess. Familial risk of inflammatory bowel disease: a populationbased cohort study 1977-2011. Am J Gastroenterol 2015:564–71.
22
Thoreson R, Cullen J. Pathophysiology of inflammatory bowel disease: an overview. Surg Clin North Am 2007:575–85.
23
Torpy J, Lynm C, Golub R. Ulcerative Colitis. JAMA 2012:104.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
